Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) Return on Equity (2016 - 2025)

Traws Pharma's Return on Equity history spans 14 years, with the latest figure at 9.13% for Q4 2025.

  • Quarterly results put Return on Equity at 9.13% for Q4 2025, down 1759.0% from a year ago — trailing twelve months through Dec 2025 was 9.13% (down 1759.0% YoY), and the annual figure for FY2025 was 1.11%, down 1248.0%.
  • Return on Equity for Q4 2025 was 9.13% at Traws Pharma, down from 2.47% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 11.11% in Q1 2025 to a low of 9.13% in Q4 2025.
  • The 5-year median for Return on Equity is 0.62% (2021), against an average of 0.05%.
  • Peak annual rise in Return on Equity hit 1343bps in 2025, while the deepest fall reached -1759bps in 2025.
  • Year by year, Return on Equity stood at 0.34% in 2021, then tumbled by -85bps to 0.64% in 2022, then crashed by -153bps to 1.61% in 2023, then surged by 625bps to 8.46% in 2024, then crashed by -208bps to 9.13% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 9.13%, 2.47%, and 2.84% for Q4 2025, Q3 2025, and Q2 2025 respectively.